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In the human genome more than 400 genes encode ion channels, which are
transmembrane proteins mediating ion fluxes across membranes. Being expressed in
all cell types, they are involved in almost all physiological processes, including sense
perception, neurotransmission, muscle contraction, secretion, immune response, cell
proliferation, and differentiation. Due to the widespread tissue distribution of ion channels
and their physiological functions, mutations in genes encoding ion channel subunits,
or their interacting proteins, are responsible for inherited ion channelopathies. These
diseases can range from common to very rare disorders and their severity can be mild,
disabling, or life-threatening. In spite of this, ion channels are the primary target of only
about 5% of the marketed drugs suggesting their potential in drug discovery. The current
review summarizes the therapeutic management of the principal ion channelopathies
of central and peripheral nervous system, heart, kidney, bone, skeletal muscle and
pancreas, resulting from mutations in calcium, sodium, potassium, and chloride ion
channels. For most channelopathies the therapy is mainly empirical and symptomatic,
often limited by lack of efficacy and tolerability for a significant number of patients.
Other channelopathies can exploit ion channel targeted drugs, such as marketed
sodium channel blockers. Developing new and more specific therapeutic approaches
is therefore required. To this aim, a major advancement in the pharmacotherapy of
channelopathies has been the discovery that ion channel mutations lead to change
in biophysics that can in turn specifically modify the sensitivity to drugs: this opens
the way to a pharmacogenetics strategy, allowing the development of a personalized
therapy with increased efficacy and reduced side effects. In addition, the identification
of disease modifiers in ion channelopathies appears an alternative strategy to discover
novel druggable targets.
Keywords: ion channels pharmacology, channelopathies, physiopathology, drug discovery and development,
genetics
INTRODUCTION
Ion channels are membrane proteins that selectively regulate ion fluxes across the membranes of
cells and cellular organelles, their gating mechanism depending on changes in membrane voltage,
ligand binding or physical and chemical stimuli. The presence of distinct ion channel isoforms
and their age-dependent and tissue-specific expression allow the fine regulation of many cellular
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functions, such as cell excitability, contraction, neurotransmitter
and hormone release, gene expression, ion and water homeostasis
(Hibino et al., 2010; Jan and Jan, 2012; Catterall and Swanson,
2015; Jentsch, 2015; Zamponi et al., 2015).
Given the pivotal roles played by ion channels and their
extensive distribution, it is not surprising that mutations in
ion channels genes, or their interacting proteins, cause specific
inherited ion channelopathies, ranging from relatively common
ones, such as idiopathic epilepsies, to very rare diseases
(Figure 1). Despite the differences in their genetic origin
and clinical setting, ion channelopathies share some common
features regarding pathophysiology and therapeutic approach.
In general, loss- or gain-of-function mutations translate into
a principal “organ-specific” clinical phenotype (Cannon, 2015;
Spillane et al., 2016). The clinical manifestation of the disease
depends on the type of mutation and functional consequences
on channel activity, the cellular and subcellular localization
of the channel isoform, and the channel oligomeric assembly
(Kullmann and Waxmann, 2010). Since first discovery, the
clinical spectrum of most channelopathies has broadened as
new carrier families and new mutations have been identified.
In some cases, the range of symptoms associated with specific
channelopathies are not easily explained at a molecular and
functional level and, besides the disease-causing mutation in
a particular ion channel gene, they might stem from the
interplay of different genes and life conditions acting as
disease modifiers (Kullmann and Waxmann, 2010; Kearney,
2011; Furby et al., 2014; Swaggart and McNally, 2014; Portaro
et al., 2015). Other channelopathies are further complicated by
comorbidity, including seizures, myotonia, neurodevelopmental
delay, arrhythmias, or diabetes that led to the definition of
multiorgan syndromes. As a consequence of such genetic and
clinical complexity and of the rarity of affected patients, a
precise diagnosis for several channelopathies is still difficult
to be made and a genotype-phenotype correlation cannot
be easily defined. This, in turn, can subtsantially affect the
choice of the most appropriate therapeutic management. The
elevated cost of drug discovery restrains the development of
new drugs for these rare diseases that are generally neglected
by pharmaceutical companies. Furthermore, as patients’ groups
are very small, clinical trials of statistical significance are
difficult to run. A few channelopathies, such as sodium
channel myotonias (SCMs) or neonatal diabetes, may benefit
from a targeted pharmacotherapy (Desaphy et al., 2013b;
De Franco et al., 2015). In some cases, a pharmacogenetic
approach have been explored successfully (Yang et al., 2012;
Desaphy et al., 2013b). Yet, most of inherited channelopathies
lack specific treatments, and medications for these disorders
are often empiric and symptomatic, acting, for instance, to
restore membrane excitability or counteract inflammation and
pain (Spillane et al., 2016). Notoriously, these drugs are
marginally effective and may work inconsistently in different
patients.
Today, about 5% of the available marketed drugs are small
molecules able to modulate ion channel activity in a number
of diseases. Some of these compounds are also enrolled in the
clinical management of channelopathies. Nav channels blockers
have been successfully employed for decades as anticonvulsants,
antiarrhythmics, and local anesthetics (Catterall and Swanson,
2015). Great interest is emerging from the possibility to develop
sodium channel inhibitors for the treatment of neuropathic pain
and to repurpose marketed blockers for other medical indications
(Desaphy et al., 2013a, 2014; Matthews and Hanna, 2014; de
Lera Ruiz and Kraus, 2015). KCNQ openers have been placed
in clinics for their anticonvulsant effects (Humphries and Dart,
2015) and KATP channels are promptly targeted by sulfonylureas
in neonatal diabetes (De Franco et al., 2015). Calcium channels
blockers are widely used as symptomatic antiarrhythmics.
Conversely, chloride channels represent a relatively under-
explored target class for drug discovery (Verkman and Galietta,
2009; Imbrici et al., 2015a; Jentsch, 2015). Unfortunately,
several drugs targeting ion channels, such as sodium channel
modulators, are not able to discriminate among ion channel
isoforms, hence at risk of causing unwanted side effects (Catterall,
2014; Grunnet et al., 2014). With a few exceptions, much-needed
specific ion channels modulators are lacking.
Therefore, to guarantee patients suffering from channel-
opathies a personalized therapy, novel molecules are under
development and pharmacological strategies have been
explored to identify novel drug targets. In principle, the
better understanding of the genetic and functional defects
underlying channelopathies will allow to deliver patients a
precision medicine specifically targeting the biological effects of
the disease-causing mutation, such as a biophysical or folding
defect. Drug design and development are being greatly assisted
by the recently identified crystal structures of several ion
channels, by computer modeling, by high-throughput screening
methods, by novel genetic studies and, finally, by transgenic
and pharmacologically induced cell and animal models of
channelopathies (Feng et al., 2010; Hibino et al., 2010; Jan
and Jan, 2012; Tikhonov and Zhorov, 2012; Pas¸ca et al., 2014;
Jentsch, 2015; Rubinstein et al., 2015; Zamponi et al., 2015; Zou,
2015). Here we summarize the main pharmacological strategies
performed to treat major channelopathies caused by mutations in
voltage-gated and inward rectifying ion channels. Although, the
involvement of other classes of ion channels and transporters,
including neurotransmitter-gated channels (Spillane et al.,
2016), cyclic nucleotide-gated channels, volume-regulated and
calcium-activated anion channels (Hoffmann et al., 2015) is also
well-established in channelopathies, these are not detailed in this
review. Finally, although rare, some channelopathies may serve
as a useful paradigm for understanding and treatment of more
common multifactorial disorders.
MOLECULAR MECHANISMS OF ION
CHANNELOPATHIES
Inherited channelopathies result from loss or gain of function
mutations in genes coding for ion channels or their accessory
subunits. Genetic variants include small deletions, insertions,
frame-shifts, stop codons, missense, splice-site mutations and,
recently, also exon deletions or duplications have been reported
(Catterall, 2014; Imbrici et al., 2015b; Spillane et al., 2016). The
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FIGURE 1 | Schematic diagram illustrating the main inherited ion channelopathies of CNS, PNS, skeletal muscle, heart, kidney, pancreas, and bone.
majority of inherited mutations alter ion channel biophysical
properties, such as voltage-dependent gating, kinetics, single
channel conductance, ion selectivity, or modulation by signaling
pathways. Some mutations reduce channel surface expression as a
consequence of altered synthesis, defective folding and trafficking
to the membrane, or increased degradation (Bechi et al., 2015;
Mall and Galietta, 2015). In general, loss-of-function mutations
in K++ or Cl− channels or gain-of-function mutations in Ca2+
or Na+ channels lead to hyperexcitability disorders, such as
epilepsy or myotonia. However, gain-of-function mutations of
neuronal K+ channels or loss-of-function mutations of Na+
channels that decrease excitability in inhibitory interneurons can
lead to epilepsy as well. Thus, the final effect of a mutation
depends on the specific expression pattern, exact stochiometry
and functional role of the ion channels involved. This knowledge
is fundamental to design appropriate therapies.
CENTRAL NERVOUS SYSTEM
CHANNELOPATHIES
Epilepsy
Epilepsy is a brain disorder due to abnormal synchronous
discharges of neuronal networks in the brain that causes
convulsions, muscle spasms, and often loss of consciousness
(Spillane et al., 2016). A broad spectrum of epileptic syndromes
exists, often comorbid with other clinical features, such as
autistic traits and other psychiatric conditions and with cardiac
arrhythmias (Splawski et al., 2004; Sicca et al., 2011; Catterall,
2014; Guglielmi et al., 2014). Different classes of ion channels
play critical roles in maintaining the balance between excitatory
and inhibitory inputs in the brain, thus it is no surprise that
gain or loss of function mutations in their genes are associated
to epilepsy.
Diverse voltage gated sodium channel subtypes, ensuring
action potential generation and propagation in the CNS (Nav1.1,
Nav1.2, Nav1.3, and Nav1.6) have been associated with multiple
seizure disorders (Catterall, 2014). More than 300 mutations in
SCN1A (Nav1.1) are responsible for genetic epilepsy syndromes
ranging in severity from simple febrile seizures to Generalized
Epilepsy with Febrile Seizures (GEFS+), an autosomal dominant
epilepsy disorder associated to missense mutations, to Severe
Myoclonic Epilepsy of Infancy (SMEI or Dravet syndrome;
prevalence: <1/40,000), the most severe form of often intractable
epilepsy mainly caused by truncation or deletion mutations
in Nav1.1 channels (Catterall, 2014). Dominant mutations
in SCN2A encoding Nav1.2 channels cause Benign Familial
Neonatal-Infantile Seizures (BFNIS; prevalence: <1/1000,000), a
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mild seizure syndrome that responds positively to treatment with
anti-epileptic drugs (AEDs), and generally remits by 1 year of age
(Berkovic et al., 2004). In addition, de novo mutations in Nav1.2
can cause more severe phenotypes including developmental
delay and intractable seizures (Ogiwara et al., 2009; Liao
et al., 2010). Other epileptic phenotypes have been associated
with mutations in SCN3A (Nav1.3), SCN8A (Nav1.6), and in
SCN1B (Nav1.1 β subunits; Vanoye et al., 2013; Larsen et al.,
2015; O’Malley and Isom, 2015; Wagnon and Meisler, 2015).
Electrophysiological and behavioral studies on mouse models
of SMEI and GEFS+ indicated that progressive loss of Nav1.1
activity in inhibitory GABAergic interneurons may cause reduced
GABA release and network hyperexcitability in different brain
regions, resulting in seizure syndromes of increasing severity
(Tang et al., 2009; Catterall, 2014; Rubinstein et al., 2015).
Beside epilepsy, impairment in GABAergic interneurons also
contributes to autistic-like behavior, hyperactivity and cognitive
impairment observed in SMEI patients (Bender et al., 2012;
Rubinstein et al., 2015).
Voltage-dependent potassium channels concur to action
potential repolarization and resting membrane potential, set the
firing frequency of neurons and dampen abnormal excitatory
inputs. Moreover, inward rectifier potassium channels contribute
to the maintenance of resting potential and to the transport
and buffering of K+ across membranes. Thus, disruption of K+
channels in specific brain areas is often associated with increased
susceptibility to seizures (for reviews see D’Adamo et al., 2015b;
Miceli et al., 2015a). Patients affected by episodic ataxia type 1,
a form of episodic ataxia with myokymia (see below) caused by
loss-of-function mutations in KCN1A (coding for Kv1.1 channel),
often report abnormal EEGs, and several animal models carrying
kcna1 gene defects show an increased susceptibility to seizures
(Smart et al., 1998). Loss- and gain-of-function mutations in
KCNA2 (encoding the potassium channel Kv1.2) have been
identified in patients with epileptic encephalopathy, intellectual
disability, delayed speech development and sometimes ataxia
(Syrbe et al., 2015). Loss-of-function mutations in KCNQ2
or KCNQ3 (encoding for Kv7.2 and Kv7.3 channels) cause
Benign Familial Neonatal Convulsions (BFNC; prevalence: 100
reported families), a form of juvenile epilepsy characterized
by tonic or clonic episodes spontaneously disappearing during
the first year of life (Miceli et al., 2015a). In the brain,
heteromeric channels composed of Kv7.2 and Kv7.3 subunits
underlie the M-current that regulates neuronal excitability in
the sub-threshold range for action potential generation and
limits repetitive firing (Soldovieri et al., 2011). A decrease in
M-current amplitude by 25% is sufficient to cause neonatal
epilepsy of variable clinical severity depending on the extent
of K+ channel impairment caused by the specific mutation.
Remarkably, de novo gain-of-function mutations in Kv7.2
channels have been found in neonates affected by early-onset
epileptic encephalopathy presenting with pharmacoresistant
seizures and various degrees of developmental delay (Miceli et al.,
2015b). In this case, the gain of potassium current in inhibitory
interneurons likely increases the excitability of hippocampal
CA1 pyramidal neurons leading, in turn, to epilepsy. Recently,
several gain of function mutations in KCNT1 gene (coding
for Kca4.1, a sodium-activated potassium channel also named
Slo2.2 or SLACK) have been identified in patients with two
different types of epilepsy occurring in infancy or childhood:
Malignant Migrating Partial Seizures of Infancy (MMPSI; also
called Epilepsy of Infancy with Migrating Focal Seizures,
EIMFS; prevalence: <1/1000,000) and Autosomal Dominant
Nocturnal Frontal Lobe Epilepsy (ADNFLE; prevalence: over
100 reported families; Lim et al., 2016; Tang et al., 2016). In
these patients, intellectual disability and psychiatric features
have also been observed. Gain-of-function mutations in the
KCNJ10 gene (coding for the Kir4.1 potassium channel) have
been reported in children with autistic traits, seizures and
intellectual disability (Sicca et al., 2011; Guglielmi et al.,
2014). Other genes of potassium channel and their accessory
subunits have been implicated in complex epileptic phenotypes,
including KCNV2 (Kv8.2), KCNMA1 (BK), KCNH5 (Kv10.2),
KCNC1 gene (Kv3.1), KCND2 (Kv4.2; Guglielmi et al., 2014;
D’Adamo et al., 2015b; Miceli et al., 2015a; Spillane et al.,
2016).
Some studies reported polymorphisms or mutations in the
chloride channel genes CLCN2 (ClC-2) and CLCN1 (ClC-1)
in epileptic patients but the involvement of these channels
in epilepsy remains controversial (Saint-Martin et al., 2009;
Niemeyer et al., 2010; Chen et al., 2013). One study also
showed the unexpected location of ClC-1 mRNA transcripts and
protein in several mouse and human brain areas, opening new
perspectives to the role of the “skeletal muscle” ClC-1 channels in
regulating brain excitability and susceptibility to seizures (Chen
et al., 2013). Defects in ClC-2, in the astrocytic membrane
protein MLC1 and in the adhesion molecule GlialCAM, underlie
human leukoencephalopathies, degenerative disorders affecting
the white matter of the brain and associated with myelin and
astrocyte vacuolization (Depienne et al., 2013; Hoegg-Beiler
et al., 2014). Mutations in both MLC1 and GlialCAM, have
been associated with rare megalencephalic leukoencephalopathy
with subcortical cysts (MLC1 and 2; prevalence: <1/1000,000),
characterized by macrocephaly, developmental delay and seizures
that appears in the first years of life (López-Hernández et al.,
2011). It has been recently shown that GlialCAM, MLC1 and ClC-
2 interact in vivo, with GlialCAM targeting both MLC1 and ClC-2
to astrocytes junctions and increasing ClC-2 chloride current,
and MLC1 also affecting the localization of ClC-2 and GlialCAM
in the glia (Hoegg-Beiler et al., 2014; Brignone et al., 2015).
Despite the pathophysiology of MLC remains unclear, studies
from different genetic animal models suggest that reduction or
change in ClC-2 currents may at least in part account for the
impaired glial ion homeostasis in both MLC forms (Blanz et al.,
2007).
Gain of function mutations in the calcium channel gene
CACNA1C (coding for Cav1.2 channel), is associated with
Timothy syndrome (TS; prevalence: <1/1000,000), a rare
multiorgan system disorder that comprises long QT syndrome,
seizures, autistic traits, dysmorphic features, developmental delay
and immunodeficiency (Splawski et al., 2004; Bader et al., 2011;
Diep and Seaver, 2015). Children die prematurely mainly for
cardiac ventricular fibrillation (Heyes et al., 2015). Gain-of-
function mutations in CACNA1H (Cav3.2) channels have been
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found in various forms of idiopathic generalized epilepsies, such
as absence epilepsy (Eckle et al., 2014; Wang et al., 2015). Studies
from an animal model carrying one Cav3.2 mutation associated
with childhood absence epilepsy suggest that Cav3.2 mutant
channels potentiate NMDA-mediated synaptic transmission via
increasing local Ca2+ influx at cortical synapses, thus enhancing
the susceptibility to absence-like epilepsy (Wang et al., 2015).
Pharmacology and Drug Therapy
Common therapeutic strategies adopted to treat different
epileptic syndromes include the positive modulation of inhibitory
GABAergic transmission, the decrease of excitatory transmission
through the inhibition of voltage-gated sodium and calcium
channels and other various mechanisms. Regardless of the genetic
origin, different AEDs such as benzodiazepines, stiripentol,
topiramate, retigabine, and Nav blockers are available on
the market and are effective in suppressing the abnormal
neuronal firing underlying epileptic seizures (Catterall, 2014;
Table 1). Despite the numerous available treatments, a large
proportion of patients still present drug-resistant seizures and
experience frequent adverse drug reactions. Thus new more
effective therapeutic options are evaluated by several research
groups and pharmaceutical companies to fulfill the need of a
personalized medicine, assisted by advances in understanding
disease mechanisms and ion channel structures (Catterall, 2014;
Walker et al., 2015).
Phenytoin, carbamazepine, lamotrigine, and valproate are
well-known state- and frequency-dependent non-selective Nav
inhibitors, binding to the local anesthetic receptor site in the
channel pore, according to the modulated receptor hypothesis,
and preferentially stabilizing channels in the non-conducting
inactivated state (Catterall and Swanson, 2015). Although
they lack Nav isoform specificity, these blockers should allow
a selective inhibition of action potential generation in the
depolarized and rapidly firing cells that are responsible for
epilepsy, leaving unaffected normally functioning tissues. These
drugs are widely used for partial and generalized epilepsy but not
for absence epilepsy (Catterall, 2014). Among sodium channel
blockers recently approved as AEDs, it is worth mentioning
lacosamide and eslicarbazepine, that shift the slow inactivation
curve of the Nav channel to more hyperpolarized potentials
and enhance the maximal fraction of channels that are in the
slow inactivated state (Rogawski et al., 2015; Soares-da-Silva
et al., 2015). In addition, current efforts in sodium channel
pharmacology are focused to develop subtype-selective Nav
channel ligands with improved safety and efficacy compared
to first generation of Nav blockers. Interestingly, several
antidepressant drugs have been shown to block sodium channels,
and this action may contribute to their anticonvulsant effects
(Igelström and Heyward, 2012). Of note, blockade of voltage-
gated sodium channels also results in inhibition of glutamate
release, which is associated with anticonvulsant effect.
In Dravet syndrome, as well as in other SCN1A-related seizure
disorders, sodium channel blockers such as carbamazepine,
lamotrigine, phenytoin are contraindicated as they may increase
frequency and severity of seizures (Catterall, 2014; Miller and
Sotero de Menezes, 2014; Schoonjans et al., 2015). In children
with SCN1A-related epilepsies, seizure control is particularly
critical as they are at high risk for sudden unexplained
death in epilepsy. In addition, there are clinical evidences
that controlling seizures will reduce the subsequent brain
injury and frequent comorbidity with cognitive impairment.
In agreement with reduced GABAergic tone in SCN1A-
related seizures, enhancement of GABAergic transmission in
inhibitory interneurons would be the most beneficial therapeutic
intervention. Indeed, treatment of conditional Scn1a+/− mouse
model of SMEI with low-dose clonazepam protected against
myoclonic and generalized tonic-clonic seizures and completely
rescued the abnormal social behaviors and deficits in fear
memory (Bender et al., 2012; Oakley et al., 2013). At present,
the standard treatment to treat SMEI children in Europe is
either the combination of stiripentol, valproate and clobazam, or
valproate in combination with topiramate (Miller and Sotero de
Menezes, 2014; Schoonjans et al., 2015). Stiripentol has obtained
orphan drug status for the treatment of SMEI in Europe (Prunetti
and Perucca, 2011). Evidences from an animal model with
haploinsufficiency for Scn1a and Scn8a suggested that reduction
in the activity of Nav1.6 channels expressed in excitatory neurons
might be an alternative useful option for Nav1.1-associated
seizures in SMEI (Chen et al., 2008; de Lera Ruiz and Kraus,
2015). Recently, levetiracetam, which binds to the synaptic vesicle
protein SV2A, was shown to be effective in GEFS+, as add-on
therapy in SMEI, and in a broad range of epilepsy syndromes
(Catterall, 2014).
Even though a selective channel opener might be a particularly
effective AED for Nav1-associated syndromes due to loss-of-
channel function, no such drug has been developed to date
(de Lera Ruiz and Kraus, 2015). Recently, different rescuing
approaches have been explored to increase surface expression
and restore the correct functioning of sodium channel mutants
associated to GEFS+ and SMEI that present folding defects
in vitro (Bechi et al., 2015). In addition, although sodium channel
β subunit-specific drugs have not yet been developed, this protein
family is an emerging therapeutic target (O’Malley and Isom,
2015).
Quinidine, an antiarrhythmic and antimalarial drug, proved
effective in reversing the increased current of KCNT1 mutants
in vitro and in remitting seizures in three patients with KCNT1
mutations resistant to multiple antiepileptic agents (Lim et al.,
2016). However, this drug acts on various cardiac potassium
channels and could possibly lengthen the QT interval and
lead to cardiac arrest. Thus, development of specific KCNT1
channel inhibitors with good blood–brain barrier penetration
may provide a safer and more effective alternative in affected
patients (Lim et al., 2016).
Another strategy to balance excitation and inhibition in
the brain consists in incrementing potassium currents, such
as KCNQ/Kv7 currents. The first agent proven to enhance
M-current activity was retigabine that has recently been
approved as a first-in-class AED for the treatment of resistant
partial-onset seizures (Humphries and Dart, 2015). Retigabine
stabilizes the Kv7 open channel conformation and induces a
hyperpolarizing shift of the activation curve (Grunnet et al.,
2014; Miceli et al., 2015a). Yet, the drug shows limited
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TABLE 1 | Central nervous system channelopathies.
Disease Gene (protein) Pharmacotherapy Pharmacological
perspectives
Epileptic syndromes including
GEFS+, SMEI,
BFNIS, BFNC,
MPSI, ADNFLE,
MLC, absence epilepsy and
other epileptic
encephalopathies
(see text for abbreviations)
SCN1A (Nav1.1)
SCN2A (Nav1.2)
SCN3A (Nav1.3)
SCN8A (Nav1.6)
SCN1B (Nav2.1)
KCNA1 (Kv1.1)
KCNA2 (Kv1.2)
KCNC3 (Kv3.3)
KCND2 (Kv4.2)
KCND3 (Kv4.3)
KCNQ2 (Kv7.2)
KCNQ3 (Kv7.3)
KCNH5 (Kv10.1)
KCNJ10 (Kir4.1)
KCNJ11 (Kir6.2)
ABCC8 (SUR1)
KCNMA1 (KCa1.1)
KCNT1 (KCa4.1)
CACNA1C (Cav1.2)
CACNA1A (Cav2.1)
CACNA1H (Cav3.2)
CLCN2 (ClC-2)
GLIALCAM
Antiepileptic drugs aim at reducing neuronal
hyperexcitability with different mechanisms:
– Enhancement of GABAergic transmission:
benzodiazepines, phenobarbital, valproate,
stiripentol, topiramate
– Inhibition of glutamatergic transmission: topiramate
– Inhibition of Nav channels: phenytoin,
carbamazepine, lamotrigine, valproate, topiramate,
lacosamide, eslicarbazepine
– Opening of K channels: retigabine, acetazolamide
– Inhibition of T-type Cav channels: ethosuximide
– Inhibition of the synaptic vescicle 2A: levetiracetam
– Inhibition of presynaptic Cav2 channels α2δ auxiliary
subunit: gabapentin, pregabalin
– Inhibition of carbonic anhydrase: topiramate,
acetazolamide
– Development of
subtype-selective Nav
channels ligands with
improved safety and efficacy
– Development of
pharmacological chaperones
for folding defective mutants
of Nav, Kv and ClC channels
– Development of more
selective and safer Kv
openers
Episodic and spinocerebellar
ataxias
KCNA1 (Kv1.1)
CACNA1A (Cav2.1)
KCNC3 (Kv3.3)
KCND3 (Kv4.3)
Symptomatic drugs aim at restoring cerebellar
functioning and reducing frequency, duration and
severity of attacks:
– Inhibition of carbonic anhydrase: acetazolamide, in
EA1 and EA2
– Inhibition of Kv channels: 4-aminopyridine, first
choice in EA2
– Riluzole: Nav channels blocker and SK and TWIK
channels opener, in cerebellar ataxias
– Opening of SK channels to
restore Purkinje cells
pacemaking: chlorzoxazone
and 1-EBIO, in EA2 animal
models
– Kv1.1 dysinactivators
Familial hemiplegic migraine CACNA1A (Cav2.1)
SCN1A (Nav1.1)
Symptomatic and prophylactic drugs aim at reducing
frequency and painful attacks:
– Tricyclic antidepressants, β-blockers, triptans, Cav
blockers, AEDs, acetazolamide
– Botulinum toxin
selectivity among all the neuronal Kv7 channel subtypes and
possesses significant activation of GABAA receptors. Because
of short half-life, retigabine requires a high and frequent
dosing regimen that, together with the relatively poor selectivity,
contributes to relevant adverse effects, including sedation, blue
skin discoloration and eye abnormalities. Thus, more selective
Kv7.2 activators are under development (Grunnet et al., 2014).
Among AEDs, ethosuximide is a fist-line treatment of
childhood absence seizures (CAE), acting through inhibition
of low-threshold T-type calcium channels (comprising Cav3.1,
3.2, and 3.3 channels) that are generally believed to contribute
to increasing seizures susceptibility. Perplexingly, about 50% of
CAE patients did not respond to ethosuximide, and the majority
of the non-responders carry Cav3.2 gain-of-function mutations
(Chen et al., 2003; Glauser et al., 2013). Recently, studies from
the first animal model of Cav3.2-linked absence epilepsy raised
the possibility to reduce slow wave discharges through NMDA
and AMPA receptors antagonists but not T-type calcium blockers
(Wang et al., 2015).
The gabapentinoid drugs, pregabalin and gabapentin,
have emerged in recent years as promising therapeutic
options in epilepsy and chronic pain. They target primarily
the α2δ auxiliary subunit of the presynaptic Cav2 channels,
thereby altering their membrane trafficking and inhibiting
excitatory neurotransmission (Catterall and Swanson,
2015).
Current treatment for megalencephalic leukoencephalopathy
is only symptomatic, including management of seizures and
spasticity with topiramate and carbamazepine (Batla et al., 2011;
van der Knaap and Scheper, 2011).
Cerebellar Ataxias and Migraine
The episodic ataxias are a group of rare autosomal dominant
diseases characterized by recurrent attacks of vertigo and
cerebellar ataxia (Jen et al., 2007). Episodic ataxia type 1
(EA1) is caused by loss-of-function mutations in the voltage-
dependent potassium channel gene KCNA1 (D’Adamo et al.,
2015b). Affected patients display constant myokymia and short
Frontiers in Pharmacology | www.frontiersin.org 6 May 2016 | Volume 7 | Article 121
fphar-07-00121 May 7, 2016 Time: 11:45 # 7
Imbrici et al. Pharmacotherapy of Ion Channelopathies
episodes of spastic contractions of the skeletal muscles of the
head, arms and legs, with loss of both motor coordination and
balance. The spectrum of clinical manifestations of the disease
also includes cognitive impairments, seizures, blurred vision,
neuromyotonia, migraine, short sleep phenotype (Imbrici et al.,
2011; D’Adamo et al., 2015b,a). The functional characterization
of several Kv1.1 mutations and the generation of a knock-in
animal model of EA1 (Herson et al., 2003), both suggest that
increased neuronal excitability and altered GABAergic inputs
to cerebellar nuclei likely generate the disease. Episodic Ataxia
type 2 (EA2) is the most frequent subtype of episodic ataxia
caused by loss-of- function mutations in the CACNA1A gene
encoding the alpha1A subunit of P/Q type voltage-gated Ca2+
channels (Cav2.1) mainly expressed in Purkinje and granule
cells in the cerebellum (Jen et al., 2007). EA2 is characterized
by longer attacks of ataxia compared to EA1, and is associated
with headache and nystagmus both during and between the
episodes attacks, but not myokymia (Jen et al., 2007; Graves et al.,
2008). The disorder frequently progresses toward a permanent
ataxia with cerebellar atrophy. It is generally assumed that
ataxia originates from impaired cerebellar neurotransmission
(Pietrobon, 2010); emerging data also point to a loss in the
precision of cerebellar Purkinje cells (PCs) pacemaking (Walter
et al., 2006).
Spinocerebellar ataxias (SCAs) are a very heterogeneous
group of autosomal dominant neurological disorders caused by
degeneration of the cerebellum and spinal cord. SCAs present a
wide range of phenotypes, including cerebellar ataxia, dysarthria,
extrapyramidal symptoms, oculomotor disturbance, cognitive
impairment, and epilepsy. SCA6 (prevalence: <1/1000,000)
is characterized by late onset, slowly progressive cerebellar
ataxia (Pietrobon, 2010). It is due to small expansions of a
polyglutamine stretch in the C-terminal tail of the Cav2.1
calcium channel, which likely causes an accumulation of Cav2.1
channels in the cytoplasm (Pietrobon, 2010). SCA13 (prevalence:
<1/1000,000) is caused by point mutations in the KCNC3
gene (encoding Kv3.3 channels), which affect channel function
by gain- and loss-of-function mechanisms (Minassian et al.,
2012). This channel is quite exclusively expressed in fast spiking
neurons, where its dysfunction affects firing frequency and
neurotransmitter release. Loss-of-function mutations in the
KCND3 gene (Kv4.3) have been found in patients with SCA19 and
SCA22 (prevalence: <1/1000,000; Duarri et al., 2012; Lee et al.,
2012).
Familial hemiplegic migraine type 1 (FHM1) is a rare and
severe form of migraine with hemiplegic aura associated with
cerebellar deficit in about 50% of patients (Pietrobon and
Moskowitz, 2013). FHM1 is due to gain-of-function missense
mutations, mostly affecting the pore and the voltage sensor
module of the Cav2.1 channel (Pietrobon and Moskowitz,
2013; Jen, 2015). Electrophysiological recordings from cerebellar
granule cell of a mouse model of FHM1, bearing the
voltage sensor R192Q mutation, showed increased Cav2.1
density and glutamate release and increased susceptibility to
cortical spreading depression as the pathophysiologic mechanism
underlying migraine with aura (Tottene et al., 2009; Pietrobon,
2010). FHM3 is associated with gain-of-function heterozygous
mutations in the SCN1A gene likely leading to hyperexcitability
of GABAergic interneurons (Dichgans et al., 2005; Cestèle et al.,
2013).
Pharmacology and Drug Therapy
No specific treatment exists for individuals affected by episodic
ataxias type 1 and 2, as openers of neuronal Kv1.1 and P/Q
type calcium channels are dramatically lacking (Table 1). Both
EA1 and EA2 patients are often treated with acetazolamide,
a carbonic-anhydrase (CA) inhibitor, although with variable
effectiveness and notable side effects during chronic treatment
(such as nephrocalcinosis, hyperhidrosis, paresthesia, muscle
stiffening with easy fatigability, and gastrointestinal disturbances;
D’Adamo et al., 2015b, Jen, 2015). The mechanisms of action of
this drug are still unclear and may include activation of skeletal
muscle Ca2+-activated-K+ (BK) channels or ClC-1 channels
(see below Eguchi et al., 2006; Tricarico et al., 2006). Today, 4-
aminopyridine is the treatment of choice for EA2. The drug, at
the concentrations used, likely targets the Kv1 channels, possibly
the Kv1.5 subtype, whereas at higher concentrations it blocks a
large array of K+ channels and is a proconvulsant. Its efficacy in
relieving ataxic gaits with only minor side effects was assessed first
in a pilot study for EA2 in humans and confirmed in a prospective
randomized, double blind, placebo-controlled crossover study in
familial EA with nystagmus. Actually, two randomized controlled
trials on EA2 with 4-aminopyridine versus acetazolamide are
ongoing (EAT-2-TREAT; Strupp et al., 2015).
An alternative approach for the treatment of EA2 may
consist in the activation of the widely- distributed, small-
conductance Ca2+-activated-K+ (SK) channels to improve
PCs firing. Treatment with 1-ethyl-2-benzimidazolinone or
chlorzoxazone, two SK channel activators, efficaciously restored
the correct pacemaking activity of PCs and reduced ataxia and
dyskinesia in tottering and ducky EA2 mouse models (Walter
et al., 2006; Alvina and Khodakhah, 2010a). Actually, also 4-
AP was shown to restore PC pacemaking and neurotransmitter
release in mouse models of EA2 (Alvina and Khodakhah, 2010b).
Compounds that disrupt Kv1.1 N-type inactivation induced
by β1 subunits have been developed and might be useful for
reducing neuronal hyperexcitability in diseases, such as epilepsy
and neuropathic pain, but could also be adjuvant in diseases
presenting with cognitive symptoms of hippocampal origin
(Humphries and Dart, 2015).
No specific treatments have been demonstrated effective in
progressive SCA (Table 1). Acetazolamide is used to alleviate
episodes of ataxia, and gabapentin may be beneficial to SCA6
patients (Nakamura et al., 2009; Ilg et al., 2014). Repurposing of
existing drugs is an approach that is being increasingly explored.
A 1-year randomized, double-blind, placebo-controlled trial with
riluzole, the only drug licensed for the treatment of amyotrophic
lateral sclerosis, in patients with hereditary cerebellar ataxia of
different aetiologies suggests the potential efficacy of this drug
(Romano et al., 2015). Riluzole blocks sodium channels, opens SK
channels, enhances activity of TWIK-related potassium channel-
1 (TREK-1), and reduces glutamate release, thereby decreasing
neuronal hyperexcitability. Longer confirmatory studies on larger
and disease-specific populations are, however, needed.
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The available therapy for all FHM types during an episode
of hemiplegic migraine is only symptomatic (Table 1). Standard
prophylactic drugs for frequent migraine include tricyclic
antidepressants, β-blockers, calcium channel blockers, triptans,
AEDs, and acetazolamide, but there is no evidence of clinical
efficacy on a large scale for any of these medications (Omata et al.,
2011; Diener et al., 2015; Jen, 2015).
PERIPHERAL NERVE
CHANNELOPATHIES
Pain Syndromes
As in the central nervous system, ion channels play a pivotal
role in excitability and communication in the peripheral
nervous system (PNS), consisting in the somatic, autonomic,
and sensory nervous systems. Genetic ion channelopathies
of the PNS encompass gene mutations in the voltage-gated
sodium, potassium and transient receptor potential channels
(TRP; Miceli et al., 2012; Bennett and Woods, 2014). Many
sodium channel subtypes are expressed in the PNS. The Nav1.3
channel is expressed mainly during embryogenesis, but de
novo expression has been reported after nerve injury and
inflammation, suggesting a possible role in neuropathic pain.
The Nav1.1, 1.2, and 1.6 are expressed in both the PNS and
CNS, and mutations in these channels result in epileptic diseases
(see above), while little is known about possible peripheral
symptoms. In contrast, SCNA9 (Nav1.7), SCNA10 (Nav1.8),
and SCNA11 (Nav1.9) channels are considered as specific PNS
channels (Catterall, 2012). Mutations in these channels cause
a series of familial or sporadic pain disorders (Brouwer et al.,
2014; Waxman et al., 2014; Habib et al., 2015). Loss of function
of Nav1.7 is linked to recessive congenital pain insensitivity or
hereditary sensory and autonomic neuropathy (Cox et al., 2006;
Yuan et al., 2013). Conversely, gain of function of Nav1.7 leads to
a triad of autosomal dominant familial pain syndromes, including
inherited erythromelalgia (IEM), paroxysmal extreme pain
disorder (PEPD; prevalence <1/1000,000), and painful small-
fiber neuropathy (SFN; Yang et al., 2004; Fertleman et al., 2006;
Faber et al., 2012a). Functional studies of Nav1.7 mutants suggest
that IEM mutations essentially enhance channel activation and
the channel ramp response, whereas PEPD mutations rather
impair fast and/or slow inactivation and produce resurgent
currents (Lampert et al., 2014). The SFN mutations induce
functional alterations overlapping those of IEM and PEPD. These
biophysical defects invariably enhance neuron excitability, which
accounts for pain exacerbation. Interestingly, a study recently
described a possible link between Nav1.7 mutation and the
neurodegeneration observed in SFN, because of reverse Na/Ca
exchanger-induced Ca2+ toxicity (Estacion et al., 2015). Gain of
function mutations of the Nav1.8 channel also lead to painful
SFN, showing faster recovery from inactivation, hyperpolarized
activation, or impaired fast inactivation (Faber et al., 2012b;
Han et al., 2014). While Nav1.7 and Nav1.8 channels allow
the rapid upstroke of action potentials in nociceptors, Nav1.9
channels have much slower kinetics and are active near the
resting potential, thereby lowering the excitability threshold.
Gain of function mutations of Nav1.9 were recently reported
to cause familial episodic pain (Zhang et al., 2013; Huang
et al., 2014; Leipold et al., 2015). Quite surprisingly, another
Nav1.9 mutation was associated to loss of pain sensation, likely
due to the concomitant alteration of channel activation and
inactivation resulting in a larger window current that, in turn,
causes sustained depolarization and inactivation of nociceptors
(Leipold et al., 2013, 2015).
Peripheral nerve hyperexcitability seems also related to
mutations in potassium channels underlying the M-current, such
as R207W/Q in Kv7.2 (Wuttke et al., 2007). In some cases the
disease is attributable to the generation of gating pore currents
(Miceli et al., 2012).
Only one mutation has been found in TRPA1 channel to cause
familial episodic pain syndrome type I (Kremeyer et al., 2010).
The enhanced activation of mutant channel by endogenous
mediators likely accounts for the intense pain experienced by
carriers.
In addition, besides the pathogenic mutations, some single
nucleotide polymorphisms found in various ion channels,
including Nav1.7, have been shown to contribute to altered pain
sensations in various conditions (Bennett and Woods, 2014;
Brouwer et al., 2014).
Pharmacology and Drug Therapy
The familial pain disorders can be severely disabling and require
the use of analgesics in addition to cold compress. At the
moment, therapeutic management of these channelopathies is
generally very difficult, often requiring combined medication
(Table 2). Controlled trials of drug effectiveness are lacking,
and the choice of drug relies mainly on physician experience.
Acetaminophen and non-steroidal anti-inflammatory drugs may
give some pain relief, but a significant number of patients
get no response (Estacion et al., 2015; Leipold et al., 2015).
In addition, the response to neuropathic pain medications,
such as antidepressants and gabapentinoids, is quite variable
between individuals. Recently, intrathecal ziconotide, a calcium
channel blocker, have proved beneficial in a woman with
primary erythromelalgia, with reduction of burning pain and
net improvement of lower extremity edema (Russo et al., 2015).
Targeting Nav channels to modulate chronic/neurpathic pain
is a widely used strategy. For example, topical lidocaine patch
is considered a first or second-line drug to treat localized
neuropathic pain, such as post-herpetic nevralgia or diabetic
neuropathy (Finnerup et al., 2015). Also the analgesic effect of the
local anesthetic butamben, used through epidural administration
to alleviate chronic pain, might be due to modulation of Nav
channels (Shulman et al., 1998, 2000; McCarthy et al., 2002;
Thériault et al., 2014). The use of sodium channel blockers may
appear straightforward to reduce nociceptor hyperexcitability
due to gain of function Nav mutations. A study reported a
satisfactory response to lidocaine patch in about one-half of
34 patients suffering from primary erythromelalgia (Davis and
Sandroni, 2005). A Nav1.7 mutation was shown to affect the
binding of the local anesthetic, which may explain in part the
significant proportion of non-responders (Sheets et al., 2007).
Only one IEM mutation has been shown to increase Nav1.7
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TABLE 2 | Peripheral nervous system channelopathies.
Disease Gene (protein) Pharmacotherapy Pharmacological
perspectives
Painful syndromes
Inherited erythromelalgia (IEM),
paroxysmal extreme
pain disorder (PEPD), painful
small-fiber neuropathy (SFN),
familial episodic pain syndrome
(FEPS)
SCN9A (Nav1.7)
SCN10A (Nav1.8)
SCN11A (Nav1.9)
TRPA1 (Trpa1)
Symptomatic therapy aims at alleviating pain with
different mechanisms of action:
– Tricyclic and SNRI Antidepressants
– Gabapentinoids
– Ziconotide, a calcium channel blocker
– Nav blockers such as lidocaine and carbamazepine
– Acetaminophen and NSAIDS
– Opioids
– Development of potent
and/or selective sodium
channel blockers for
neuropathic and
inflammatory pain
– Capsaicin or lidocaine
patches
– Botulinum toxin
– Cannabinoids
Painless syndromes
Congenital insensitivity to pain,
Idiopathic small fiber
neuropathy
SCN9A (Nav1.7) No drug available
channel sensitivity to mexiletine, likely contributing to the
favorable response to the drug observed in this specific patient
(Choi et al., 2009). Carbamazepine, a sodium channel blocker
indicated for trigeminal neuralgia, was reported to be effective
in 14 PEPD patients although the response was incomplete
(Fertleman et al., 2007). The drug was also effective in an IEM
family members carrying a Nav1.7 mutation with enhanced
carbamazepine sensitivity (Fischer et al., 2009). One may expect
that such studies will help to design a pharmacogenetics strategy
to identify the most effective drug for each mutation, as predicted
by in silico studies (Yang et al., 2012). Nevertheless, treatment
of the PNS channelopathies remains in most cases an unmet
medical need.
By demonstrating unambiguously the pivotal role Nav1.7, 1.8
and 1.9 channels in pain sensation, the discovery of PNS Nav
channelopathies have paved the way for the development of
potent and/or selective sodium channel blockers for application
in neuropathic and inflammatory pain (Ghelardini et al., 2010;
Theile and Cummins, 2011; Bagal et al., 2014; Carbonara et al.,
2015). Some of these drugs have entered clinical trials, but
whether they will be helpful to treat channelopathies remains to
be verified.
SKELETAL MUSCLE
CHANNELOPATHIES
Non-dystrophic Myotonias
Non-dystrophic myotonias include myotonia congenita (MC;
prevalence 1-9/100,000), paramyotonia congenita (PMC) and
SCM. They all share a common symptom, myotonia, that is
characterized by impaired muscle relaxation after contraction
and is evident as typical “myotonic runs” at EMG (Cannon,
2015).
Myotonia congenita is caused by loss-of-function mutations
in the CLCN1 gene coding for the skeletal muscle chloride
channel ClC-1 (Imbrici et al., 2015b). It can be inherited in a
dominant (Thomsen) and recessive (Becker) form, this latter
presenting with a more severe myotonic phenotype, frequent
transient weakness, and sometimes myopathic signs. Myotonia
improves with exercise, according to the so-called “warm-up”
phenomenon. Alterations of ClC-1 have been reported also in
myotonic dystrophies and in Duchenne muscular dystrophy (De
Luca et al., 2003; Cardani et al., 2012); although the underlying
mechanisms are different, these alterations can account for
common membrane hyperexcitability signs. The ClC-1 channel
normally dampens membrane excitability and stabilizes the
resting membrane potential after an action potential (Jentsch,
2015). Thus, the reduced chloride conductance resulting from
MC mutations predispose the sarcolemma to spontaneous action
potential runs or abnormal afterdischarges that hamper muscle
relaxation after contraction, causing myotonia.
Dominantly inherited missense mutations in the SCN4A
gene encoding the skeletal muscle voltage-gated sodium channel
Nav1.4 cause either PMC or SCM (Cannon, 2015). PMC
is characterized by early onset muscle stiffness that worsens
with cold and exercise (hence paradoxical). Patients often
experience muscle weakness that can last several hours. In
contrast, SCM presents with different degrees of pure myotonia
without weakness. Laryngospasm is a life-threatening symptom
reported in neonates carrying some SCM mutations, leading
to the description of a new clinical entity called severe
neonatal episodic laryngospam (SNEL; Lion-Francois et al.,
2010). In heterologous expression systems, sodium channel
mutants usually show impaired fast inactivation with enhanced
activation or not (Cannon, 2015). Slowed inactivation has been
suggested to induce resurgent Na currents due to re-opening
of Na+ channels during repolarisation (Jarecki et al., 2010).
The net effect of these gain-of-function disturbances is an
increase in Na+ entry into the muscle fibers, which allows
repetitive discharges that persist beyond the duration of the
stimulus.
Pharmacology and Drug Therapy
Today, the sodium channel blocker mexiletine represents the
first line therapy for the myotonic syndromes, irrespective
of the culprit gene (Table 3). This drug can be effective in
reducing stiffness and transient weakness in non-dystrophic
myotonias and myotonic dystrophy (Statland et al., 2012;
Lo Monaco et al., 2015). Nevertheless its use is limited by
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TABLE 3 | Skeletal muscle channelopathies.
Disease Gene (protein) Pharmacotherapy Pharmacological perspectives
Non-dystrophic myotonias
including myotonia congenita
(MC), paramyotonia congenita
(PMC), and sodium channel
myotonia (SCM)
CLCN1 (ClC-1)
SCN4A (Nav1.4)
Symptomatic (MC) and targeted (PMC and SCM)
therapy aims at reducing skeletal muscle
hyperexcitability:
– Mexiletine (first choice), carbamazepine, flecainide,
propafenone are use-dependent Nav channels
blockers
– Charbonic anydrase inhibitors such as
acetazolamide likely increase BK channels activity
and ClC-1 channels open probability
– Enhancement of Nav slow inactivation
with ranolazine and lacosamide
– Repurposing of marketed Nav blockers,
such as riluzole
– Development of more selective and
use-dependent Nav blockers
– Development of ClC-1 channel activators
and pharmacological chaperones for MC
– Development of a pharmacogenetics
approach
Periodic paralysis (PP) including
hyperkalemic periodic paralysis
(HyperPP), hypokalemic
periodic paralysis types 1 and 2
(HypoPP1 and 2),
Andersen-Tawil syndrome,
tyreotoxic periodic paralysis
SCN4A (Nav1.4)
CACNA1S (Cav1.1)
KCNJ2 (Kir2.1)
KCNJ6 (Kir2.6)
Symptomatic therapy aims at reducing frequency and
severity of paralytic attacks and at restoring serum K+
levels:
– Carbonic anhydrase inhibitors such as
acetazolamide and dichlorphenamide (orphan drug
for PP) likely increase BK channels activity and ClC-1
channels open probability
– The β2-agonist salbutamol and glucose/insulin
activate Na+/K+-ATPase and restore serum K+
levels in HyperPP
– Potassium supplements or K+ sparing diuretics in
HypoPP
– Benzothiazide diuretics such as hydrochlorothiazide
in HyperPP
– Development of guanidinium derivatives
and other Igp blockers in HypoPP
– Development of KATP openers selective
for skeletal muscle channels
– Bumetanide, a loop diuretic that inhibits
the Na/K/2Cl co-transporter, was useful
in a mouse model of HypoPP
country availability, side effects and limited or null response
in some patients (Desaphy et al., 2013b; Matthews and Hanna,
2014; Suetterlin et al., 2015). In vitro and in vivo studies
have shown that the variable clinical efficacy of mexiletine
in SCM patients may rely on the different sensitivity of
specific mutant channels to the drug (Figure 2; Desaphy et al.,
2001, 2004, 2013b). Thus, the functional characterization of
biophysical defect caused by each mutation could help to
predict patients’ responsiveness to a drug and to address the
more appropriate therapy. Recently, ranolazine and lacosamide,
drugs used to treat angina and epilepsy respectively, have been
shown to enhance slow inactivation of sodium channels and
thus suggested as an alternative to mexiletine in MC non-
responders (Novak et al., 2015). In parallel, other sodium
channel blockers on the market for different therapeutic
indications, such as riluzole, are under investigation as possible
alternatives to mexiletine (Desaphy et al., 2013a, 2014).
Finally, a series of structure-activity studies of mexiletine
and tocainide derivatives have been performed to develop
Nav1.4 channels blockers a 100 times more potent and use-
dependent than parental compounds, which may prove useful
in myotonic conditions (Talon et al., 2001; De Luca et al.,
2004; Carocci et al., 2010; De Bellis et al., 2013; Muraglia et al.,
2014).
The carbonic anhydrase inhibitor acetazolamide has been
used with variable success in myotonia (Benstead et al., 1987;
Trudell et al., 1987; Markhorst et al., 2014). One possible
mechanism accounting for membrane electrical stabilization
by acetazolamide consists in the opening of skeletal muscle
BK calcium-activated potassium channels (Tricarico et al.,
2006). More recently, the drug was proposed to increase
ClC-1 open probability, probably through a change in pHi
(Eguchi et al., 2006). It is however possible that the significant
percentage of non-responders stems from a reduced sensitivity
of some mutant channels to the drug (Desaphy et al.,
2013c).
A specific pharmacological treatment for MC patients
is lacking. The ideal drug to treat ClC-1 channelopathy
should be one able to increase chloride currents, but this
goal is far from being achieved. The R(+)-isomer of 2-(p-
chlorophenoxy) propionic acid has been shown to increase
the skeletal muscle chloride conductance (De Luca et al.,
1992). However, a direct effect on heterologously expressed
ClC-1 channels has not been observed (Pusch et al., 2000).
Insulin-like growth factor-1 or taurine, as well as PKC
inhibitors, such as staurosporine or chelerythrine are also
able to enhance chloride conductance (Pierno et al., 1994,
2003; De Luca et al., 1998). Although they lack a direct
therapeutic interest, compounds able to block gCl, such as
9-anthracen carboxylic acid, clofibric acid derivatives, and
niflumic acid can be useful pharmacological tools to develop
animal models of myotonia or to investigate hClC-1structure-
function relationship (Liantonio et al., 2007; Desaphy et al.,
2014).
Periodic Paralyses
Opposed to myotonia are the familial periodic paralyses
(PP), which are rare (1/100,000) autosomal-dominant disorders
characterized by transient loss of muscle excitability leading
to attacks of flaccid paralysis with weakness (Cannon, 2015;
Suetterlin et al., 2015). The PP are classified as hyperkalemic PP
(hyperPP; prevalence: 1-9/1000,000), hypokalemic PP (hypoPP;
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FIGURE 2 | Pharmacogenetics of myotonic sodium channel mutants. (A,B) Representative sodium current traces from hNav1.4 WT channels and myotonic
G1306E mutants recorded in transfected cells at steady-state before and during application of mexiletine at 0.1 and 10 Hz stimulation frequencies.
(C) Concentration-effect relationships for mexiletine on WT and G1306E, fitted to a first-order binding function. (D,E) Effects of flecainide on sodium currents in the
same conditions as in (A,B). (F) Concentration-effect relationships for flecainide on WT and G1306E. The G1306E mutation impairs mexiletine inhibition, while
leaving flecainide affinity unchanged. Consequently, patients carrying G1306E, who suffer form a severe form of myotonia, obtained significant improvement by
shifting treatment from mexiletine to flecainide.
prevalence: 1-9/100,000), or Andersen-Tawil syndrome (ATS),
and are caused by mutations of sodium (Nav1.4), calcium
(Cav1.1), and several inward-rectifier potassium channels (Kir2.1,
Kir2.6, and Kir3.4). HyperPP is associated with abnormally
elevated serum K+ ions levels up to 6 mEq/L triggered
by ingestion of potassium-rich food, rest after strenuous
exercise, and cold exposure. The pathomechanism in hyperPP
is explained by the gain-of-function mutations of Nav1.4. The
mutant channels display impaired inactivation, resulting in
persistent sodium influx and cell depolarization, which in turn
inactivates Nav1.4 channel (Cannon, 2015). The depolarization
in hyperPP amplifies K+ ions eﬄux from the muscle through
K+ channels that elevate the serum K+ ions concentration
contributing to the paralysis (Khogali et al., 2015). In hypoPP,
blood potassium concentration decreases below 3.2 mEq/L
triggered by rest after strenuous exercise, by a meal rich in
carbohydrates, or by exposure to cold. Familial forms of hypoPP
are caused by SCN4A (20%) and CACNA1S (60%) mutations
of positively charged residues in the channel voltage sensor
that create an aberrant permeation pathway for H+ or Na+
ions, resulting in depolarizing cation leak currents named
gating pore currents (Igp; Moreau et al., 2014). The fiber
depolarization in the hypoPP is therefore due to an unbalance
between the depolarizing Igp and repolarising Kir and sarco-
KATP channel currents (Tricarico et al., 2008b). Administration
of insulin/glucose activates the 3Na+/2K+-ATPase causing a
marked hypokalemia, which reduces gene expression/activity of
Kir channels (Tricarico et al., 2003, 2008b). All these factors
contribute to the fiber depolarization that inactivates Nav1.4
and Cav1.1 channels with paralysis (Tricarico and Camerino,
2011).
Andersen-Tawil syndrome is a multiorgan disease
characterized by PP, cardiac arrhythmias, and skeletal
malformations (Tawil et al., 1994). Paralysis may occurs
with either hyperkalemia or hypokalemia associated with various
heart manifestations including long QT syndrome (LQT7, see
below). Mutations in KCNJ2 cause the disease by suppressing
Kir2.1 currents and/or enhancing inward currents, due to
dominant negative effects or haplo-insufficiency (Davies et al.,
2005). Some KCNJ2 mutations decrease PIP2 sensitivity or
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exaggerate the inhibitory effects of intracellular Mg2+ or proton.
A novel mutation of KCNJ5 encoding Kir3.4 channel exerts a
dominant negative effect on Kir2.1 in heart and skeletal muscle
of ATS patients (Kokunai et al., 2014).
Thyrotoxic periodic paralysis (TPP), associated to
hyperthyroidism, is the most common cause of hypokalemic
flaccid muscle paralysis in adults. Mutations of KCNJ18
encoding the Kir2.6 channel have been found in a few cases
of TPP and of sporadic PP (SPP) not necessarily associated
to thyrotoxicosis (Ryan et al., 2010; Cheng et al., 2011). The
mutants show reduced or no current and exert dominant
negative inhibition of wild-type Kir2.6 and Kir2.1 channels.
The Kir down-regulation predisposes to hypokalemia-
induced paradoxical depolarization during attacks. Other
susceptibility genetic variants for TPP and SPP include rs623011
and SUR1Ala1369Ser. The former reduces Kir2.1 channel
transcription in skeletal muscle independently of thyroid
hormone (Jongjaroenprasert et al., 2012), while the latter
encodes an auxiliary subunit of KATP channel in pancreatic beta
cells, fast twitching muscle fibers and heart (Wheeler et al., 2008;
Rolim et al., 2014).
Very recently, the spectrum of muscle channelopathies with
pronounced weakness has been widened by the discovery of novel
Nav1.4 mutations causing congenital myasthenic syndrome with
PP or severe fetal hypokinesia (Zaharieva et al., 2015; Habbout
et al., 2016).
Pharmacology and Drug Therapy
Drug therapy of PP can be separated into two categories,
treatments used for acute attacks and prophylactic treatments
(Table 3). In hyperPP, acute attacks may respond to inhaled
salbutamol or glucose/insulin therapy that exert their
repolarizing actions by activating the 3Na+/2K+-ATPase
and restoring the serum K+ levels. In hypoPP, acute attacks
are usually treated with oral potassium chloride glucose-free.
The treatment of the hyperkalemia or hypokalemia can be
successfully achieved by administrating benzothiazide diuretics
(hydrochlorothiazide) or K+ sparing diuretics, respectively.
The most effective medication for prevention of attacks in
both disorders remains the carbonic anhydrase inhibitors,
acetazolamide and dichlorphenamide. Dichlorphenamide
has been recently designed as orphan drug for the treatment
of primary periodic paralyses. A very recent clinical trial
demonstrated significant efficiency of dichlorphenamide in
hypoPP but not hyperPP (Sansone et al., 2016). These drugs
ameliorate paralysis reducing frequency of the attacks and
vacuolar myophathy in human and animal models of hypoPP
(Tricarico et al., 2006, 2008a; Matthews and Hanna, 2014). One
of the main mechanisms responsible for their therapeutic effects
relies on their capability to open calcium-activated potassium BK
channels in muscle fibers (Tricarico et al., 2006, 2013; Dinardo
et al., 2012). Yet, in some hypoPP patients, acetazolamide fails to
prevent paralysis and may show detrimental effects. For instance,
none of the patients with glycine substitutions, i.e., R528G,
R1239G, or R672G, respond satisfactorily to acetazolamide but
are still responsive to dichorphenamide (Bendahhou et al., 2001;
Sternberg et al., 2001; Kim et al., 2007).
Recently, bumetanide, a loop diuretic that inhibits the
Na+/K+/2Cl− co-transporter, proved effective in preventing
weakness attacks in a mouse model of hypoPP, thereby
representing a novel symptomatic strategy (Wu et al., 2013).
The treatment of ATS is complicated by the need to address
two distinct phenotypes, PP and cardiac arrhythmias (Nguyen
et al., 2013). PP therapy includes minimizing known triggers
and prophylaxis with acetazolamide. Potassium supplementation
may also prevent paralytic attacks while simultaneously
shortening the QT interval. Treatment of cardiac arrhythmias
forecasts the use of β-blockers or flecainide. No specific
treatment is available to address muscle weakness in TPP.
Acetazolamide should not be used in these patients due to risk
of adrenergic symptoms aggravation. Drugs targeting KATP
and/or Kir channels in skeletal muscle may be of interest to
treat PP. The available KATP channel openers show a poor
tissue selectivity and Kirs openers are not available (Humphries
and Dart, 2015). Thus, KATP channel openers have been
proposed in PP but their use is limited by the side effects
(Tricarico and Camerino, 2011; Tricarico et al., 2012). The
search for KATP channel openers acting selectively in skeletal
muscle is underway (Rolland et al., 2006; Tricarico et al., 2008a,
2012).
One logical strategy to treat PP may consist in blocking the
Igp, without affecting normal channel gating, however no drug
is currently available. A few gating pore blockers have been
tentatively identified, including divalent and trivalent cations
such as gadolinium (Sokolov et al., 2007, 2010; Struyk and
Cannon, 2007). Some guanidinium derivatives block Igp but in
millimolar concentration range. Differences in the environment
surrounding the gating pores may however affect drug responses
to this class of compounds (Moreau et al., 2014). In addition,
natural toxins can represent interesting lead compounds as
Igp blockers, such as those able to stabilize the voltage sensor
(Moreau et al., 2014).
HEART CHANNELOPATHIES
Heart Arrhythmias
Cardiac channelopathies encompass a large spectrum of
heart diseases characterized by arrhythmic events, conduction
defects, and cardiomyopathies (Campuzano et al., 2015; Spears
and Gollob, 2015). They are among the leading causes of
sudden cardiac death (SCD) in young people, with a marked
male prevalence. The four principal groups of proarrhythmic
channelopathies are long QT syndrome (LQTS; prevalence:
1/2,500), short QT syndrome (SQTS), Brugada syndrome
(BrS; prevalence: 1/3,300 to 1/10,000), and catecholaminergic
polymorphic ventricular tachycardia (CPVT; prevalence:
1/10,000). Besides the four main cardiac channelopathies,
ion channel gene mutations have been linked to a plethora
of rare familial cases of cardiomiopathies. For instance,
SCN5A mutations can cause not only LQT3 and BrS, but
also cardiac conduction disease, sick sinus syndrome, atrial
fibrillation, or dilated cardiomyopathy (Remme and Wilde,
2014).
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The first heart channelopathy to be discovered was a
congenital form of long QT syndrome (LQT1) due to mutations
in KCNQ1 encoding the main subunit (Kv7.1) of the K channel
responsible for the slow delayed rectifier current (IKs) in
cardiomyocytes (Wang et al., 1996). LQT1 mutations induce
a loss of function of Kv7.1, which delays action potential
termination and increases the electrocardiogram QT interval
longer than 470/480 ms (male/female), thereby increasing the
risk of early after discharges (EADs), ventricular arrhythmia,
torsades de pointes, seizures, syncope, and sudden death. Since
then, at least fifteen genetic subtypes of LQTS have been reported,
including nine forms linked to mutations in genes encoding ion
channel subunits, while the others are caused by mutations in
proteins that secondarily alter ion channel function or calcium
signaling (Spears and Gollob, 2015). LQTS mutations induce
either loss of function of K+ channel subunits or gain of function
of Na+ or Ca2+ channels.
Conversely, gain of function of K+ channels or loss of function
of Ca2+ channels accelerates the action potential termination,
thereby shortening the QT duration (Brugada et al., 2004;
Betzenhauser et al., 2015). SQTS is a rare but very severe
condition characterized by a QT interval minor to 350/360 ms,
which eventually leads to SCD during rest, sleep, or exercise at an
early age. Very recently, carnitine deficiency due to mutations in
the SLC22A5 gene encoding the ubiquitary membrane carnitine
transporter OCTN2, have been associated to SQT, likely due to
secondarily increased K+ channel activity (Roussel et al., 2016).
The BrS is characterized by various ECG alterations, especially
an elevation of the ST segment followed by a negative T wave
(Havakuk and Viskin, 2016). The more frequent mutations
are found in SCN5A gene encoding Nav1.5 sodium channel
(Chen et al., 1998). Mutations in SCN5A as well as SCN1B
or SCN3B, both encoding auxiliary β-subunits, all reduced
Na+ currents. A reduction of INa is also involved in BrS
due to mutations of the glycerol-3-phosphate dehydrogenase
GPD1L gene. Loss of function mutations are found in genes
coding for the L-type Ca2+ channel in individuals showing
overlapping BrS and SQT. Familial dysfunction of the sinoatrial
and atrioventricular nodes has been also associated with
mutations in HCN4 channels, cationic channels involved in
pacemaker activity (Milanesi et al., 2015). Loss of function
in HCN4 have been observed in rare BrS cases. One gain-
of-function mutation in the same channel, R504Q, has been
found in a family with inappropriate sinus tachycardia (IST),
a syndrome characterized by abnormally fast sinus rate and
multisystem symptoms (Baruscotti et al., 2015). Gain of function
of the KCNE3 β-subunit of K+ channels responsible for the
transient outward current Ito are found in less than 1% of BrS
cases.
The CPVT is characterized by ventricular arrhythmias
triggered by physical exercise, emotional stress, or catecholamine
administration, in the absence of structural heart disease.
Without treatment, CPVT has a high mortality rate. Mutations
in the RyR2 ryanodine receptor, an intracellular calcium channel,
were the first identified to cause CPVT (Priori et al., 2002).
Mutations in other proteins involved in Ca2+ handling, including
calsequestrin-2, triadin, and calmodulin, have been also reported.
It is also worth to note that some of these channelopathies
can affect different organs; for instance, LQT7 syndrome
caused by KCNJ2 mutations corresponds to Andersen-Tawil
syndrome, which is characterized by a triad of ventricular
arrhythmias, periodic paralysis, and dysmorphic features (see
above). Similarly, CACNA1C mutations cause LQT8 in Timothy
syndrome.
Pharmacology and Drug Therapy
In cardiac channelopathies, syncope is often the first presenting
symptom and the risk of SCD is very high. The genetic testing can
give invaluable information to support diagnosis in the patient
and prognosis in familiars, and to address treatment in both. The
management of syncope survivors and relatives at high risk often
consists in the use of an implantable cardioverter defibrillator
(ICD) to correct or interrupt life-threatening arrhythmias.
In some cases, such as SQTS and BrS, ICD is the only proven
therapy. Only a preliminary study suggests that quinidine may
be effective in SQT1, likely due to its ability to block open
Herg channels (Gaita et al., 2004). In BrS, either quinidine or
isoproterenol, which increases the L-type calcium current, may
be used to manage refractory and acute arrhythmias, but data
are lacking to recommend these drugs as ICD alternative (Priori
et al., 2013). Intravenous class 1 antiarrhythmic drugs, such
as flecainide or ajmaline, are used as provocative tools of ST
elevation for BrS diagnosis.
In both LQTS and CVPT, emotional stress and intense exercise
play a prominent role in triggering ventricular arrhythmias.
Thus the main pharmacological approach consists in the use of
β-adrenoceptor antagonists to reduce sympathetic or adrenergic
stimulation. The preferred drug in CPVT is nadolol, a long
acting β-blocker lacking intrinsic sympathomimetic activity
(Priori et al., 2013). To obtain a better response, high dosage
and strict compliance to therapy are required, together with
exercise restriction. Flecainide, an antiarrhythmic with mixed
action on Nav1.5 and RyR2 channels, may be added to
prevent breakthrough arrhythmias on β-blockers. An integrated
approach to the diagnosis, risk stratification, and genotype-
and phenotype-guided management of patients with LQTS has
been recently provided for by Giudicessi and Ackerman (2013).
Nadolol and propranolol are recommended for the treatment of
all LQTS subtypes. Blockers of late Na current, such as mexiletine
or ranolazine, may be used as add-on therapy for LQT3 (Ruan
et al., 2007; Moss et al., 2008). However, some SCN5A mutations
impair mexiletine effects and the drug may favor Na channel
trafficking to the membrane, thus raising concerns about the
indiscriminate use of sodium channel blockers in LQT3 without
careful individual testing (Ruan et al., 2007, 2010). In case of
unsatisfactory response or non-compliance to β-blockers, the left
cardiac sympathetic denervation (LCSD) may prove useful in
both CPVT and LQTS, although randomized control trials to
evaluate the risk/benefit of this treatment are lacking.
No gene mutation have been identified in most cases of SCD,
thus it is likely that the number of cardiac channel mutations will
continue to increase. Despite the large number of ion channels
causing cardiac arrhythmias, the therapeutic options are limited
and based mostly on symptomatic treatments, with only rare
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exceptions (Table 4). It is expected that future studies will be
dedicated to the search of gene- or mutation-specific approaches
(El-Sherif and Boutjdir, 2015).
KIDNEY CHANNELOPATHIES
Bartter’s Syndrome
Bartter’s syndromes (BS; prevalence: 1/1000,000) are a
heterogeneous group of rare salt loosing tubulopathies
confined mainly at the level of thick ascending limb (TAL)
of Henle’s loop (Loudon and Fry, 2014). BS type III is
due to loss of function mutations of CLCNKB gene and is
characterized by polyuria, polydipsia, hypokalemia, alkalosis,
hypercalciuria and frequently nephrocalcinosis (Simon et al.,
1997; Krämer et al., 2008). CLC-Kb chloride channels are
expressed, together with their accessory subunit, barttin, at the
basolateral membrane of TAL and distal convoluted tubule
(DCT), where they permit NaCl reabsorption, and in the
stria vascularis of the inner ear, where they contribute to the
mechanism for K+ secretion into endolymph (Estévez et al.,
2001). Deletion, nonsense, and missense CLCNKB mutations
have been reported, which usually cause a disruption of
channel trafficking to the plasma membrane or a reduction
of channel open probability (Andrini et al., 2015). Missense
and nonsense mutations in BSDN, encoding barttin, result in
antenatal BS type IV, the most severe BS form, characterized
by excessive polyhydramnios and prematurity with early failure
to thrive and sensorineural deafness (Janssen et al., 2009; de
Pablos et al., 2014). In addition, impaired palmitoylation of
some barttin mutants may play a role in chloride channel
dysfunction (Steinke et al., 2015). Conversely, gain-of-function
polymorphisms in CLCNK genes have been reported to be
associated with salt retention and hypertension (Barlassina et al.,
2007).
The Kir1.1 (or ROMK) channel encoded by KCNJ1 is the major
secretory channel in the kidney (Welling and Ho, 2009). ROMK
loss-of-function mutations cause BS type II, characterized by
antenatal presentation of polyhydramnios, premature delivery,
profound postnatal polyuria, hypokalaemia, hyponatraemia and
hypercalciuria, as well as secondary nephrocalcinosis later in
life (Simon et al., 1996; Brochard et al., 2009). The defective
TABLE 4 | Heart channelopathies.
Disease Gene (protein) Pharmacotherapy Pharmacological
perspectives
Long QT syndrome (LQTS) KCNQ1 (Kv7.1)
KCNH2 (HERG)
KCNE1 (Mink)
KCNE2 (MiRP1)
KCNJ2 (Kir2.1)
KCNJ5 (Kir3.4)
SCN5A (Nav1.5)
SCN4B (Nav2.4)
CACNA1C (Cav1.2)
Non-channel:
AKAP9 (yatio)
CALM1 (calmodulin)
CALM2 (calmodulin)
CAV3 (caveolin)
SNTA1 (syntrophin a1)
ANKB (ankyrin B)
Symptomatic therapy aims at restoring normal heart
rhythm:
– Implantable cardioverter defibrillator (ICD)
– β-adrenoceptor antagonists, such as nadolol and
propranolol, plus flecainide.
– Mexiletine or ranolazine can be used as add-on
therapy in LQT3
– Left cardiac sympathetic denervation (LCSD) when
β-blockers fail
Gene- and mutation- specific
drugs
Short QT syndrome (SQTS) KCNH2 (HERG)
KCNQ1 (Kv7.1)
KCNJ2 (Kir2.1)
– Implantable cardioverter defibrillator (ICD)
– Quinidine, a class I antiarrhythmic, in SQT1 owing to
HERG channels block
Brugada syndrome (BrS) SCN5A (Nav1.5)
SCN1B (Nav2.1)
SCN3B (Nav2.3)
KCNE3 (MiRP2)
CACNA1C (Cav1.2)
CACNB2 (Cavβ2)
HCN4 (Hcn4)
Symptomatic therapy aims at restoring normal heart
rhythm:
– Implantable cardioverter defibrillator (ICD) is the only
available option
– Quinidine (K channel blocker) or isoproterenol (L-type
calcium current activator) are used for acute
arrhythmias. Their use as an alternative to ICD
remains to be verified
Gene- and mutation-specific
therapy
Catecholaminergic polymorphic
ventricular tachycardia (CPVT)
RYR2 (RyR2)
Non-channel:
CASQ2
(calsequestrin-2)
CALM1 (calmodulin-1)
TRDN (triadin)
Symptomatic therapy aims at restoring normal heart
rhythm:
– high doses of β-blockers, such as nadolol, plus
flecainide
– Left cardiac sympathetic denervation (LCSD) where
β-blockers fail
– Gene- and mutation-
specific drugs
– Gene therapy in mouse
models
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function of ROMK channel mutants impairs K+ movement
from intracellular compartment to TAL lumen (Boim et al.,
1995).
Pharmacology and Drug Therapy
Management of patients with BS is oriented toward acute and
chronic therapy of presenting complications and abnormalities
(Nascimento et al., 2014; Table 5). Fluid and electrolyte
replacement led to an immediate amelioration of the symptoms.
Long-term treatment in BS consists of a high-salt diet, potassium
and magnesium replacement, and potassium-sparing diuretics,
such as spironolactone/eplerenone and amiloride. In addition,
volume depletion leads to upregulation of prostaglandin E2
by both renal and non-renal mechanisms. Indomethacin,
a cyclooxygenase inhibitor, has been used extensively in
the treatment of BS and proved efficient in increasing
height and body weight, and reducing hyperfiltration. It
can frequently induce gastrointestinal complications, such as
gastritis, bleeding ulcers, and necrotizing enterocolitis, especially
in infants. Definitely, BS therapy remains empirical with
one limiting factor represented by the drug-induced risk of
progressive renal damage, which can lead to chronic renal
failure (Unwin and Capasso, 2006). The identification of
therapy of targeting the molecular defect is therefore urgently
needed.
NFA, a non-steroidal anti-inflammatory drug belonging to
fenamate, resulted the unique molecule able to activate CLC-K
channel expressed in Xenopus oocytes (Liantonio et al., 2008).
Although this effect was not reproduced in mammalian cells
(Imbrici et al., 2014), NFA may represent a lead compound to
create novel optimized ligands to treat BS types III and IV.
Despite the lack of CLC-K openers, CLC-K selective blockers
exist and may have a therapeutic potential in hypertension
(Figure 3). Preclinical studies performed in normotensive and
hypertensive rats showed that in vivo administration of small-
molecules inhibitors of CLC-K channels induced diuretic and
antihypertensive effects with no toxic effect (Liantonio et al.,
2012, 2016; Imbrici et al., 2014).
Similarly to CLC-K, molecular pharmacology of Kir1.1
(ROMK) remains quite limited. No Kir channel opener is
known (Humphries and Dart, 2015). Since ROMK is expressed
in both TAL and CCD, inhibitors may provide superior
diuretic/natriuretic efficacy as compared to loop diuretics, which
exert their effects in TAL only. A high throughput screening
study identified 1,4-bis(4nitrophenethyl)piperazine derivatives as
potent ROMK inhibitors (Garcia and Kaczorowski, 2014). In
normotensive animals, short-term oral administration of one of
these derivatives caused concentration-dependent diuresis and
natriuresis that were comparable to hydrochlorothiazide (Garcia
et al., 2014).
Dent’s Disease
Mutations in CLCN5 gene cause a subtype of Dent’s disease
type 1 (prevalence: 250 reported families), a renal tubular
disorders characterized by low molecular weight proteinuria,
hypercalciuria, nephrolithiasis, nephrocalcinosis, and progressive
renal failure (Lloyd et al., 1997; Hodgin et al., 2008). CLCN5
encodes the CLC-5 protein, which functions as an electrogenic
2Cl−/H+ antiporter (Picollo and Pusch, 2005). In human kidney,
CLC-5 is expressed in proximal tubule (PT), thick ascending
limb, and intercalated cells of collecting ducts. In PT cells, CLC-5
co-distributes with the vacuolar H+-ATPase in early endosomes,
which are responsible for the reabsorption and processing of
albumin and low molecular weight proteins filtered by the
glomerulus. Thus, the disease is essentially due to defective
TABLE 5 | Kidney channelopathies.
Disease Gene (protein) Pharmacotherapy and mechanisms of action Pharmacological perspectives
Bartter’s syndrome (BS)
including types II–IV
CLCNKB (ClC-Kb), BSDN
(Barttin), ROMK1 (Kir1.1)
Symptomatic therapy aims at restoring electrolyte
balance:
– Potassium-sparing diuretics such as
spironolactone/eplerenone and amiloride restore
serum K+ concentrations
– Indomethacin, a COX inhibitor, reduces PGE2
production
– Potassium and magnesium supplements restore
electrolyte balance
– Development of selective channel openers
through a pharmacogenetic approach
– Development of pharmacological
chaperones
Dent disease type 1 CLCN5 (ClC-5) Symptomatic therapy aims at restoring electrolyte
balance:
– Thiazide diuretics ameliorate hypercalciuria
– High citrate and fluid intake control hypercalciuria
– Vitamin D counteracts rickets in clinical cases with
additional bone disease
– Development of CLC-5 activators
– Development of pharmacological
chaperones
EAST/SESAME syndrome KCNJ11 (Kir4.1) Symptomatic therapy aims at restoring electrolyte
balance and remitting seizures:
– Antiepileptic drugs
– Indometacin
– Oral potassium
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FIGURE 3 | Electrophysiological drug testing on expressed chloride channels and docking simulation. (A) Representative CLC-Ka patch-clamp
recordings from transfected HEK293 cells, before and after the application of a synthetic compound, SRA-36. (B) Dose-response curve of CLC-Ka current inhibition
by SRA-36 measured at +60 mV. (C) Model of the SRA-36 top-scored docking pose resulting from Induced Fit Docking simulations using a homology model of
ClC-Ka modeled on the crystal structure of ClC-ec1.
receptor-mediated endocytosis causing a generalized dysfunction
of PT cells. The two constitutive CLC-5 knock-out mouse
models (Piwon et al., 2000; Wang et al., 2000), both exhibit
the most common features of Dent’s disease, but differ in other
characteristics, potentially reflecting the phenotype variability
observed in patients. The use of a knock-in mouse harboring a
point mutation that converts the exchanger into an uncoupled
Cl− channel discloses the importance of chloride concentration
for organelle physiology (Novarino et al., 2010). The recent
analysis of a large cohort of patients confirmed that CLCN5
mutations can be divided into three different functional classes
affecting the dimerization process, helix stability or ions transport
(Mansour-Hendili et al., 2015; Pusch and Zifarelli, 2015).
Pharmacology and Drug Therapy
The current care of patients with Dent’s disease is supportive,
focusing on the prevention of nephrolithiasis relying mainly
on generous liquid intake (Table 5). Thiazide diuretics can be
used to treat hypercalciuria, although significant adverse events,
including hypovolemia and hypokalemia related to primary
tubulopathy have been reported (Raja et al., 2002). Similarly,
treatment with vitamin D must be cautious since it may increase
hypercalciuria. Studies performed on CLC-5 deficient mice
suggest that a high-citrate diet can preserve renal function and
slow progression of renal disease (Cebotaru et al., 2005). A major
future challenge will be to search for specific molecules able to
restore CLC-5 mutant function in Dent’s disease patients, but
CLC-5 ligands are lacking. Available ligands for other CLC family
members could serve as starting molecular structures to reach
such an objective.
EAST/SeSAME Syndrome
EAST/SeSAME syndrome (seizures, sensorineural deafness,
ataxia, mental retardation, and electrolyte imbalance syndrome;
prevalence: <1/1000,000) is a multiorgan disorder that presents
with a unique set of symptoms including epilepsy, ataxia, mental
retardation, hearing loss, and electrolyte imbalance related to
renal salt loss (Bockenhauer et al., 2009). It is caused by
missense or deletion mutations in KCNJ10 (Kir4.1 channels)
that compromise the function of homomeric Kir4.1 expressed in
kidney DCT, glial cells in the brain and spinal cord, and in the
inner ear (Sala-Rabanal et al., 2010; Cross et al., 2013).
Pharmacology and Drug Therapy
No specific therapy exists for affected patients (Table 5).
Seizure control is achieved with typical AEDs. Potassium
supplementation accompanied by indometacin administration
has also been reported (Cross et al., 2013).
ENDOCRINE CHANNELOPATHIES
Neonatal Diabetes Mellitus and
Congenital Hyperinsulinism
In pancreatic beta cells, the main ATP-sensitive K+ channel
(KATP) complex is formed by the assembly of Kir6.2/SUR1
subunits (Babenko et al., 2000). This channel regulates insulin
secretion in response to glucose challenge, and is involved in
genetic diseases associated with insulin/glucose dismetabolism.
Loss-of-function mutations in KCNJ11 and ABCC8 genes
underlie familial congenital hyperinsulinism, while gain-of-
function mutations and metabolic uncoupling are associated
to neonatal diabetes mellitus (prevalence: 1/300,000-400,000)
and DEND syndrome with developmental delay, epilepsy and
neonatal diabetes (McTaggart et al., 2010; Arnoux et al., 2011).
Pharmacology and Drug Therapy
It is known that SUR1 subunit carries the binding sites for
the KATP channel blockers, such as glibenclamide, tolbutamide,
glimepiride, repaglinide, and nateglinide, acting as insulin-
releasing agents in diabetes therapy, and for the KATP channel
opener diazoxide used as a hyperglycaemic drug (Babenko et al.,
2000). The most used medications in the treatment of congenital
hyperinsulinism are diazoxide and somatostatin analogs (Welters
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et al., 2015; Table 6). While insulin therapy is commonly
prescribed in neonatal diabetes, glibenclamide is effective in
resolving the CNS and peripheral symptoms in patients carrying
KCNJ11 and ABCC8 mutations replacing insulin therapy (De
Franco et al., 2015). However, patients carrying the Gly334Val
KCNJ11 mutation, are not responsive to this drug (Lau et al.,
2015).
Osteopetrosis and Other Bone
Abnormalities
Osteopetrosis (OP; prevalence: 1/250,000) is a heterogeneous
genetic condition characterized by increased skeletal mass and
results from reduced function of osteoclasts and impairment of
bone resorption. Defects in TCIRG1, encoding a vacuolar-ATPase
subunit, account for nearly 50% of all patients with OP and cause
an impairment of vesicle trafficking and lysosomal acidification
in osteoclasts leading to bone resorption defect (Sobacchi et al.,
2013). More rarely, dominant or recessive mutations are found
in CLCN7 or OSTM1 genes, encoding the lysosomal 2Cl−/H+-
transporter CLC-7 or its auxiliary subunit Ostm1 (Kornak et al.,
2001; Kasper et al., 2005; Leisle et al., 2011). Most CLC-7
mutations induce a loss of channel function; several dominant
mutations were shown to accelerate the voltage gating of CLC-7.
In mice, the disruption of CLC-7 mimics severe OP with retinal
and CNS degeneration as in the recessive form of human OP
(Kornak et al., 2001; Weinert et al., 2014). Skeletal dysplasia and
defects in bone ossification are associated with gain of function
mutations in the calcium-permeable TRPV4 ion channel gene,
which result in an increased basal intracellular Ca2+ levels (Nilius
and Voets, 2013).
Pharmacology and Drug Therapy
As osteoclasts are of hematopoietic origin, hematopoietic stem
cell transplantation (HSCT) is the only curative treatment for
various forms of recessive osteopetrosis in early life, but this
is associated with a high incidence of adverse effects such as
graft failure, hepatic and pulmonary toxicity, and veno-occlusive
disease (Orchard et al., 2015). Otherwise, OP treatment is mainly
supportive (Table 6). Calcitriol, by modulating blood calcium
level, increases osteoclasts activity and interferon γ increases
bone resorption, causing a reduction in trabecular bone area
and an increase in bone marrow space (Key et al., 1995).
Undergoing research aims at identifying selective compounds
able to open/activate CLC-7 or to slow the accelerated activation
of CLC-7 observed in several patients, and siRNA against specific
CLC-7 mutants can be feasible in some therapeutically neglected
form of osteopetrosis (Capulli et al., 2015). Conversely, CLC-
7 inhibitors as well as anti-CLC-7 antibodies could be used
to reduce bone resorption in osteoporosis (Zhao et al., 2009;
Ohgi et al., 2011). Proof of concept of gene therapy efficacy
has been obtained in mice, in which neonatal transplantation of
genetically modified stem cell, using a lentiviral vector expressing
murine TCIRG1, led to improved bone resorption (Moscatelli
et al., 2013). Encouraging preclinical treatments for OP include
in utero stem cell treatment, RANK ligand replacement therapy,
and denosumab for post-HSCT hypercalcaemia (Sobacchi et al.,
2013). A pharmacological block of TRPV4 has been also
proposed as a potential therapeutic strategy (Nilius and Voets,
2013).
FUTURE PERSPECTIVE IN DRUG
DISCOVERY
The pharmacotherapy of ion channelopathies is a challenging
issue in clinical management. To date, only a few channelopathies
can benefit from a targeted therapy while, in the majority
of cases, the current approaches rely on symptomatic and
often empiric medications limited by extensive drug resistance
and adverse events (Desaphy et al., 2013b; Lo Monaco et al.,
2015). Deciphering the exact pathogenetic mechanism for every
channelopathy is fundamental to design therapies tailored upon
patients’ requirements. The improvement and generation of
disease-related cell and animal models as well as the development
of innovative pharmacological strategies greatly help to fulfill this
aim. Below, we report some examples of the most remarkable
attempts in this direction (Figure 4).
Disease-related Models
Animal models that recapitulate human channelopathies have
been pivotal for understanding the underlying pathophysiology
and for subsequent preclinical studies (De Luca, 2012; Desaphy
et al., 2014; Fratta and Hanna, 2015; Rubinstein et al., 2015;
Zou, 2015). When possible, human cell-based approaches, such
TABLE 6 | Endocrine channelopathies.
Disease Gene (protein) Pharmacotherapy Pharmacological perspectives
Familial congenital
hyperinsulinism
KCNJ11 (Kir6.2)
ABCC8 (SUR1)
Diazoxide, a hyperglycaemic drug that opens KATP
channels, and somatostatin analogs reduce insulin
release in congenital hyperinsulinism
Neonatal diabetes
mellitus and DEND
syndrome
KCNJ11 (Kir6.2)
ABCC8 (SUR1)
Insulin and glibenclamide, a hypoglycaemic drug that
blocks KATP channels, increase insulin levels in
neonatal diabetes mellitus
Osteopetrosis CLCN7 (ClC-7)
OSTM1 (ClC-7
accessory subunit
Ostm1)
Therapy aims at increasing bone resorption:
– Hematopoietic stem cell transplantation
– Calcitriol and interferon γ
– Corticosteroids
Development of selective compounds
able to open/activate ClC-7 or to slow
the accelerated activation of some
ClC-7 mutants
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FIGURE 4 | Schematic diagram illustrating the process of drug discovery, from the analysis of disease pathophysiology to development of a
precision medicine.
as primary cell culture from patients’ biopsies and induced
pluripotent stem cells (iPSCs), may represent another fascinating
opportunity to understand human diseases, properly identify
disease pathways and conduct high-throughput drug screening.
Patients’ muscle biopsies have been recently employed to
investigate the mechanisms of the variable expressivity of
myotonia congenita phenotypes (Portaro et al., 2015). In a
gene expression study on myotonic patients’ biopsies, the
greater expression of the Na+ channel β1 subunit and the
total lack of potassium channel subunit MiRP2 were correlated
with the clinical severity of the Becker myotonic phenotype
of the affected individuals (Portaro et al., 2015). This study
not only provides evidence for a role of KCNE3 and SCN1B
genes as interesting predictors of myotonic phenotype, but also
suggests new targets for drug development. As the availability
of patients’ biopsies is often poor, the possibility to reprogram
somatic cells derived from patients into pluripotent stem
cells that can be differentiated in vitro is emerging as an
appealing opportunity for modeling channelopathies. Recently,
human skin cells from Timothy syndrome (TS) patients were
reprogrammed into iPSCs and subsequently differentiated into
cardiac muscle cells or neurons (Krey et al., 2013; Yazawa
and Dolmetsch, 2013; Pas¸ca et al., 2014). Results from these
studies showed that TS ventricular-like cardiomyocytes exhibited
deficits in contraction, electrical signaling and calcium handling,
and that the cyclin-dependent kinase inhibitor and atypical
Cav channel blocker roscovitine could successfully rescue this
cellular phenotype. Similarly, roscovitine proved efficacious in
restoring the neuronal phenotype in cortical neurons derived
from TS patients using the same approach (Krey et al., 2013).
In vitro iPSCs-based models of cerebellar ataxia and Andersen-
Tawil syndrome have also been established to recapitulate the
complex in vivo events underlying these dysfunctions (Watson
et al., 2015; Pini et al., 2016). Although fascinating, iPSCs
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technology is still challenging, one of the most crucial issue
being the need to establish a reliable disease phenotype that
can be reproduced in quite large quantities in vitro. However,
once established, it could provide an invaluable resource for drug
target identification and drug screening (Skalova et al., 2015;
Watson et al., 2015).
Pharmacological Chaperones
One promising approach to treat protein-misfolding channel-
opathies is based on pharmacological chaperones. These
molecules stabilize protein correct folding, limit premature ER-
associated degradation and promote protein delivery to the cell
surface. Ivacaftor and lumacaftor, correctors of specific CFTR
folding defective mutants, have been successfully used to rescue
CFTR dysfunction in patients affected by cystic fibrosis (Mall
and Galietta, 2015). Different proof-of-principle strategies have
been tested to restore in vitro functioning Nav channels in
GEFS+, such as the incubation of mutant sodium channels at low
temperature, the interactions with different co-expressed proteins
(such as β1 subunit, calmodulin, ankyrin G), the exposure to
sodium channel blockers such as phenytoin (Rusconi et al., 2007;
Cestèle et al., 2013; Bechi et al., 2015). Typical pharmacological
chaperones are reversible high affinity ion channels inhibitors, so
their application in rescuing misfolded mutants might be limited
by the possible block of the rescued channels correctly inserted
in the membrane. To overcome these drawbacks in GEFS+, beta
scorpion toxins peptidic derivatives were recently engineered
to bind Nav channels with high affinity and to target the ER,
and appeared more effective pharmacological chaperones than
phenytoin in vitro (Bechi et al., 2015).
Voltage Sensor Domain (VSD)
Modulators
Voltage sensitivity is provided in voltage gated ion channels
by voltage sensor domains, that allow voltage-induced
conformational changes leading to channel opening through the
interaction of highly conserved charged residues. Most drugs
targeting ion channels bind their central alpha pore. Interestingly,
disruption of VSDs, mainly due to mutations of arginine residues
has been shown to generate gating pore currents that underlie
different channelopathies, including hypoPP, peripheral nerve
hyperexcitability, epilepsy and arrhythmias (Moreau et al., 2014;
Miceli et al., 2015a). Thus, compounds modulating VSDs could
be used as research tools and could represent a very promising
pharmacological strategy for many pathologies and biophysical
defects. Examples of existing VSD modulators are compounds
blocking selectively neuronal Nav1.1/1.3/1.7 channels, specific
small molecule openers or blockers of Kv7.2 channel (Peretz
et al., 2010; McCormack et al., 2013), or guanidinium derivatives
blocking the gating currents from mutant Nav1.4 channels
(Sokolov et al., 2010). Recently, the small molecule ztz240,
selected after a wide and sophisticated screening, has been shown
to open Kv7.2 channels by binding to the F137 residue in the
gating charge pathway, and be valuable in the treatment of
epilepsy (Kornilov et al., 2013; Li et al., 2013). In addition, gating
modifier toxins that target and stabilize the VSD in the resting or
activated state, can be useful research tools for structure-function
investigations (Moreau et al., 2014; Miceli et al., 2015a).
Pharmacogenetics
In some channelopathies, the observation that the drug sensitivity
of an ion channel in vitro depends on the specific biophysical
defects carried by single disease-associated ion channel mutations
provided the basis for the development of a pharmacogenetic
approach. In particular, studies on SCMs demonstrated that
sodium channel mutations with a negative shift of the voltage
dependence of inactivation showed increased sensitivity to
mexiletine, and the corresponding myotonic carriers responded
well to this drug. Conversely, mutations that right shifted the
inactivation voltage dependence were less sensitive to mexiletine
and were preferentially blocked by flecainide (Desaphy et al.,
2001, 2004). In the respective mutation carriers, flecainide
exhibited greater benefit than mexiletine (Desaphy et al., 2013b).
In addition, mutations located close to the binding site for
mexiletine can modify sensitivity to the drug (Takahashi and
Cannon, 2001). These evidences support the idea that the
pharmacological characterization of mutant channels in vitro is
fundamental to predict drug response in vivo and address the
carrier of a specific mutation toward the appropriate therapy.
Marketed Drugs Repurposing
One recent direction of pharmacological research is based on
repurposing of existing drugs, that represents a time- and cost-
sparing strategy. Nav channel blockers that are already on
the market for another indication and can be selected as an
alternative to mexiletine to treat neuromuscular channelopathies
or cerebellar ataxias represent an example (Desaphy et al., 2014;
Matthews and Hanna, 2014; Romano et al., 2015). Importantly,
the repurposing of marketed drugs will avoid the need of trials
on safety, and, if positive results are obtained in cell and animal
models, these drugs will be entered in a phase II clinical trials.
Among novel strategies to discover ion channels selective
ligands, it is worth mentioning the search of pharmacovigilance
databases to pick commercial drugs inducing a side effect that is
endorsed to an ion channel block. Recently this strategy has been
used to monitor drug-induced atrophy that in vitro resulted from
KATP channel block using the Food and Drug Administration-
Adverse Effects Reporting System (FDA-AERS) database (Mele
et al., 2014). This database is a passive surveillance system that
collects spontaneous reports of adverse events regarding any
US licensed drugs from providers, health care workers, and the
public. Although AERS cannot usually prove causal associations
between drugs and adverse events, it can help to obtain helpful
information on drug activity that can be validated in vitro.
Novel Targets
Improved understanding of the disease pathways leads to the
selection of alternative drug targets apart from the causative
ion channel. Indeed, many disorders reflect dysfunctions in
regulatory proteins that may alter ion channel biophysical
properties, synthesis, membrane trafficking and/or post-
translational modifications and/or can modulate the phenotypic
variability observed in affected families. These proteins are
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emerging as attractive opportunities for drug development
(Bechi et al., 2015; Brignone et al., 2015). Pharmacological
correction of an ion channel defect by targeting an alternative
ion channel that may compensate for the primary dysfunction is
considered another possible approach to treat channelopathies.
Recently, activators of the epithelial Ca2+-activated Cl− channels
TMEM16A, also known as anoctamin-1 (ANO1), proved
useful in reducing sustained inflammation in cystic fibrosis
lung disease (Mall and Galietta, 2015). SK channel activators
fulfilled this scope in episodic and progressive ataxias (Walter
et al., 2006; Romano et al., 2015). Novel ion channels
classes, besides classical voltage-gated channels, have emerged
as having therapeutic potential, due to their wide distribution
and implication in the pathophysiology of several disorders.
TRPV channels modulators, for instance, are being developed
in inflammatory and neuropathic pain, migraine, focal and
segmental glomerulosclerosis, bone abnormalities and other
disorders (Kaneko and Szallasi, 2014). Recently, the much-
needed molecular identity of volume-regulated anion channel
(VRAC) composed of LRRC8 heteromers has been disclosed
(Pedersen et al., 2016). Given the pivotal role played in cell
volume regulation in all cell types and evidences suggesting
the involvement in several pathophysiological processes, VRAC
would represent a new promising target in diseases such as
cardiac hypertrophy, megalencephalic leukoencephalopathy with
subcortical cysts, cerebral ischemia and cancer (Yamamoto
et al., 2011; Brignone et al., 2015; Pedersen et al., 2016). In
addition, ivabradine, the first hyperpolarization-activated cyclic
nucleotide-gated (HCN) channel inhibitor, has been clinically
approved for the treatment of chronic stable angina pectoris and
heart failure (Cao et al., 2015). Moreover, modulators of acid-
sensing ion channels (ASIC) activity are potential candidates for
new effective analgesic and neuroprotection drugs (Baron and
Lingueglia, 2015).
Cell and Gene Therapy
Finally, the possibility to manipulate the expression of ion
channels by viral gene therapy is another strategy exploited
in neurological channelopathies such as pain, epilepsy and
muscular dystrophy, where a high percentage of non-responders
to traditional pharmacotherapy have been encountered. This
challenging approach ranges from the up- or down-regulation
of ion channels that control excitability endogenously, to
optogenetics and chemogenetics (Snowball and Schorge, 2015).
As additional ion channels are identified and characterized,
new channelopathies emerge that would deserve precision
medicine. The key to success in the clinical management of
ion channelopathies will be the discovery of more potent and
selective ion channel modulators to improve efficacy and safety
on a larger clinical scale with respect to existing treatment
options.
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